News

Ideas That Generate Results

Since its inception, the erythropoietin market of Europe has witnessed a number of technological advancements that have helped the researchers to develop new and innovative products according to our report, “European Erythropoietin Market Outlook 2022”. In this regard, the researchers have developed identical, synthetic versions of the EPO hormone, using recombinant DNA technology. By making use of this technology, this hormone can be produced in bulk amounts and can be administered easily. With the help of this technology, scientists have been able to develop second generation of erythropoietin. Darbepoetin alpha contains two additional N-linked carbohydrate chains, which confer greater metabolic stability in vivo.
 
More recently, a third-generation molecule, Continuous Erythropoietin Receptor Activator (CERA), incorporating a large polymer chain, has been developed. CERA has a half-life of 130 hours, which is longer than the half-life of either epoetin or darbepoetin alpha. CERA may also have different receptor binding characteristics and pharmacology from other erythropoietin agents. A fourth generation of erythropoietin is also being developed by making use of adenovirus with a piece of erythropoietin DNA.
 
Furthermore, efforts are also being made to increase the production capabilities of the CHO cell lines, which are used for the erythropoietin production. Recently, Batavia Biosciences have created a new technology called STEP, which enables the rapid generation of high producing stable mammalian CHO cell lines. The STEP technology provides a platform for production of recombinant proteins and antibodies in mammalian cells. STEP plasmids are equipped with elements that allow very efficient and flexible cell selection under high antibiotics pressure. Since STEP technology only yields few very high expressing cell lines, the time consumption and thus cost in manufacturing STEP cell lines is significantly reduced as compared to other stable cell line generation technologies.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM863.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm